A long-term follow-up of approximately 50,000 children who received the Hemophilus influenzae type b capsular polysaccharide vaccine in 1974 at three months to five years of age has shown good protective efficacy in those who received the vaccine at 18 months or older. No adverse effects were observed. Analysis of paired serum samples from 514 vaccinated children showed that effective immunization with this vaccine could be performed after but not before the age of 16 to 20 months. An analysis of 956 bacteremic H. influenzae infections occurring in Finland over a period of five years showed that 94 per cent of all cases were in children under 10 years of age. Of these, 40 per cent occurred in children under 18 months, and 60 per cent in children between the ages of 1 1/2 and 9 years. These 60 per cent are potentially preventable with the capsular polysaccharide vaccine.
This article has been cited by other articles:
Newton, S., Owusu-Agyei, S., Ampofo, W., Zandoh, C., Adjuik, M., Adjei, G., Tchum, S., Filteau, S., Kirkwood, B. R.
(2007). Vitamin A Supplementation Enhances Infants' Immune Responses to Hepatitis B Vaccine but Does Not Affect Responses to Haemophilus influenzae Type b Vaccine. J. Nutr.
137: 1272-1277
[Abstract][Full Text]
Finn, A.
(2004). Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull
70: 1-14
[Abstract][Full Text]
Verez-Bencomo, V., Fernandez-Santana, V., Hardy, E., Toledo, M. E., Rodriguez, M. C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., Cosme, K., Deler, M. L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, F., Campa, C., Diaz, M., Roy, R.
(2004). A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b. Science
305: 522-525
[Abstract][Full Text]
Peltola, H.
(2000). Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates. Clin. Microbiol. Rev.
13: 302-317
[Abstract][Full Text]
Hougs, L., Juul, L., Ditzel, H. J., Heilmann, C., Svejgaard, A., Barington, T.
(1999). The First Dose of a Haemophilus influenzae Type b Conjugate Vaccine Reactivates Memory B Cells: Evidence for Extensive Clonal Selection, Intraclonal Affinity Maturation, and Multiple Isotype Switches to IgA2. J. Immunol.
162: 224-237
[Abstract][Full Text]
Robinson, M J, Campbell, F, Powell, P, Sims, D, Thornton, C
(1999). Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Arch. Dis. Child. Fetal Neonatal Ed.
80: 69F-71
[Abstract][Full Text]
Concepcion, N., Frasch, C. E.
(1998). Evaluation of Previously Assigned Antibody Concentrations in Pneumococcal Polysaccharide Reference Serum 89SF by the Method of Cross-Standardization. CVI
5: 199-204
[Abstract][Full Text]
Leung, A. K.C., Chiu, A. S.K., Siu, T. O.
(1989). Subcutaneous versus intramuscular administration of Haemophilus influenzae type b vaccine. The Journal of the Royal Society for the Promotion of Health
109: 71-73
[Abstract]
Leung, A. K.C., Jadavji, T.
(1988). Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. The Journal of the Royal Society for the Promotion of Health
108: 180-181
Previous
